Lonza Group AG
Active …LONN.SW
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug …
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
39.55B CHF
Healthcare
Diagnostics & Research
Switzerland
CHF
Common Stock
- Open
- —
- High
- —
- Low
- —
- Close / last
- —
- Volume
- —
- Prev close
- —
- Change
- —
- Change %
- —
- Session date
- —
- Quote time
- —
Wall Street Target
$681.13
PE Ratio (TTM)
36.58
Forward PE
31.25
Earnings per Share
$15.48
Dividend per Share
$5.00
Market Cap
39.55B
EBITDA
2.39B
Profit Margin
-0.0160%
Dividend Yield
0.01%
Price / Sales (TTM)
5.760x
EPS Estimate (Current)
18.509
EPS Estimate (Next Year)
21.983
EV / Revenue
6.430x
EV / EBITDA
29.130x
Revenue Growth (YoY)
0.112%
Earnings Growth (YoY)
0.392%
Address
Muenchensteinerstrasse 38
Basel
4002
Switzerland
Phone
41 61 316 81 11Website
https://www.lonza.comEmployees
20141
David Carter
Head of Communications
Dr. Matthias Hofmann
Head of Corporate Environment, Health, Safety & Global Sustainability
Dr. Wolfgang Wienand Ph.D.
Chief Executive Officer
Born 1972
Mr. Andreas Bohrer
Chief Legal & Corporate Affairs Officer
Mr. Daniel Buchta
Head of Investor Relations
Mr. Jason Berndt
Executive VP & Head of Group Operations
Mr. Philippe Deecke
Chief Financial Officer
Ms. Jennifer Clancy
Senior Director of Global Marketing
Ms. Kim Harrelson
Head of Ethics & Compliance, ERM and Corporate Responsibility
Ms. Nicoleta Baumgartner
Chief Human Resources Officer
Born 1971
2026-07-22
Recent quarters & estimate trends
View full earnings (40)| Period | EPS Act. | EPS Est. | Surprise |
|---|---|---|---|
| Dec 2026 | — | — | — |
| Jun 2026 | — | — | — |
| Mar 2026 | 0.00 | 0.00 | — |
| Sep 2025 | 0.00 | 0.00 | — |
| Jun 2025 | 6.07 | — | — |
| Mar 2025 | 4.31 | 10.40 | -58.56% |
| Sep 2024 | 0.00 | 0.00 | — |
| Jun 2024 | 0.00 | 9.66 | -100.00% |
Estimate trends
Dec 2027
21.98 EPS est.
19.0% growth
Dec 2026
18.51 EPS est.
23.0% growth
Dec 2025
16.76 EPS est.
12.0% growth
Dec 2024
13.88 EPS est.
12.0% growth